Actualités Argen X SE - ARGX | Actions Euronext

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and...

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP...

argenx to Present at TD Cowen 45th Annual Healthcare Conference

February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in...

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication...

argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on...

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Argen X SE (ARGX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ARGX Actualités

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx to Participate at Upcoming Investor Conferences

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Argen X SE (ARGX) Actualités

Argen X SE (ARGX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ARGX Actualités

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx to Participate at Upcoming Investor Conferences

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités